Boehringer Ingelheim Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
9 result(s) found, displaying 1 to 9
-
Nov-2024Prescription medicine evaluationActive ingredient: spesolimab.
-
Prescription medicine registrationActive ingredients: empagliflozin.
-
Prescription medicine registrationActive ingredients: empagliflozin, metformin hydrochloride.
-
Australian Public Assessment Report (AusPAR)Jardiance (empagliflozin) has been approved for reducing the risk of kidney disease progression in adults with chronic kidney disease.
-
Australian Public Assessment Report (AusPAR)Spevigo (spesolimab) has been approved for the treatment of generalised pustular psoriasis, a rare but severe form of psoriasis that involves flares of widespread, non-infectious, macroscopically visible pustules.
-
Apr-2024Prescription medicine evaluationActive ingredient: Tenecteplase.
-
Prescription medicine registrationActive ingredients: empagliflozin.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ACTILYSE alteplase (rch) 50 mg powder for injection vial with diluent vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ATROVENT UNIT DOSE VIALS ipratropium bromide 250 micrograms/1 mL (as monohydrate) conventional inhalation ampoule.